Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
HepElimination
International
Registration and information: www.virology-education.com
PROGRAM COMMITTEE
Charles Boucher, MD, PhDErasmus Medical Center,The Netherlands
Jordan Feld, MD (co-chair 2016) University of Toronto, Toronto Western Hospital Liver Centre, Canada
Manal El-Sayed, MDAin Shams University CairoEgypt
Margeret Hellard, MBBS, PhDBurnet Institute & The Alfred Hospital Melbourne
John Ward, MDCenters of Disease Control and Prevention, USA
Stefan Zeuzem, MDJ.W. Goethe University Hospital, Germany
DEAR COLLEAGUES,
It is our pleasure to invite you for the International Viral Hepatitis Elimination Meeting 2016.
The field of viral hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. There are great hopes for the elimination of viral Hepatitis. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately the elimination of viral Hepatitis.
Commit yourself to help eliminate viral hepatitis and join us at the International Viral Hepatitis Elimination Meeting 2016.
MEETING OBJECTIVES
• Identify the roadblocks and the challenges to come to an integrated approach to eliminate viral hepatitis.
• Identify the needs from the public health perspective.
• Get a cross-disciplinary discussion started.
• Create a platform for collaboration and national action plans.
WHY SHOULD YOU ATTEND?
The workshop provides a cross-disciplinary platform for information exchange between various experts involved in the treatment of Hepatitis-infected patients. Your participation is essential in order to identify and take the necessary steps to eliminate viral Hepatitis.
WHO SHOULD ATTEND?
Medical professionals, including but not limited to Clinicians, Researchers, Public Health representatives, Industry representatives, who look beyond the individual patient and who would like to be involved in the elimination of viral Hepatitis.
Goal: Defining and implementing the pathway forward to eliminate viral hepatitis
ELIMINATION OF VIRAL HEPATITIS
3RD INTERNATIONAL MEETING ON
AMSTERDAM, THE NETHERLANDS • 1-2 DECEMBER 2016
Registration and information: www.virology-education.com
PRELIMINARY PROGRAMTHURSDAY 1 DECEMBER
13.00h Opening of the workshop
13.15h Opening lecture on WHO programs Marc Bulterys, MD, PhD, Centers of Disease Control and Prevention, USA (tbc)
Session 1: Results of National programs: Barriers & Successes
13.45h National perspectives in Europe - common themes and challengesAngelos Hatzakis, PhD, MSC, University of Athens, Greece
14.15h National Programs - Georgia - tbc
14.30h National Programs - Egypt Manal El-Sayed, MD, Ain Shams University, Egypt
14.45h National Programs - AustraliaMargaret Hellard, MBBS, FRACP, FAFPHM, PhD, Burnet Institute, Australia
15.00h National Programs - USJohn Ward, MD, Centers of Disease Control and Prevention, USA
15.15h Discussion
16.00h Coffee Break
Session 2: Progress towards elimination - Specific Populations
Chair: tbc
16.30h InmatesAndrew Lloyd, MBBS, MD, FRACP, PhD, University of New South Wales, Australia (tbc)
16.50h Children & Pregnant womenManal El-Sayed, MD, Ain Shams University, Egypt (tbc)
17.10h People who inject drugsOlav Dalgard, MD, PhD, Akershus University Hospital, Norway (tbc)
17.30h Discussion
18.00h End of Day 1 - Workshop Dinner
FRIDAY 2 DECEMBER
Session 3: Diagnosing
08.30h WHO Guidelines and Policies of testingPhilippa Easterbrook, WHO, Switzerland (tbc)
08.50h Progess in testing technologiesTeri Roberts, FIND, Switzerland (tbc)
09.10h Challenges in Monitoring (POC)Isabelle Andrieux-Meyer, Médecins Sans Frontières, Switzerland (tbc)
09.30h Challenges in regards to resistanceJean-Michel Pawlotsky, MD, PhD, University of Paris-Est, France (tbc)
09.50h Discussion
10.00h Coffee Break
Session 4: Reducing Transmission and harm
10.30h Global injection prevention WHO (include blood safety) - tbc
11.10h Prevention of infection/reinfection in high risk populationMargaret Hellard, MBBS, FRACP, FAFPHM, PhD, Burnet Institute, Australia
11.50h Creating awareness and sharing the knowledgeFabrice Olivet, Autosupport des Usagers de Drogues (ASUD), France (tbc)
11.30h Can we afford not to treat reinfectionPeter Vickerman, DPhil, University of Bristol, United Kingdom (tbc)
11.50h Discussion
12.15h Lunch
Session 5: Future scenarios for elimination
13.15h Vaccine development and resultsAndrea Cox, MD, PhD, Johns Hopkins School of Medicine, USA (tbc)
13.35h Minimising treatment duration and dosesJordan Feld, MD, MPH, University of Toronto, Canada
13.55h Role of generic drugsAndrew Hill, MD, Liverpool University, UK (tbc)
14.15h "Financial basis"Pierre van Damme, MD, PhD, University of Antwerp, Belgium (tbc)
14.35h Building global capacityJohn Ward, MD, Centers of Disease Control and Prevention, USA
14.35h Round table Discussion
15.00h Program adjournment